Showing results (391-400 of 423) with videos related to
Sort By:
Pageof 43
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.Biologicals : Journal of the International Association of Biological Standardization|October 23, 2012
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012Jonathan Kay, Brian G Feagan, Micheal S Guirguis, et al.Lancet (London, England)|June 30, 2009
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialJosef S Smolen, Jonathan Kay, Mittie K Doyle, et al.Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|January 10, 2019
Linked-read Sequencing Analysis Reveals Tumor-specific Genome Variation Landscapes in Neurofibromatosis Type 2 (NF2) PatientsDaniel S Roberts, Rahul Maurya, Yuka Takemon, et al.Annals of the Rheumatic Diseases|August 12, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase IJulia Funovits, Daniel Aletaha, Vivian Bykerk, et al.Trials|March 19, 2025
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trialAlexis Ogdie, Soumya M Reddy, Sarah H Gillespie, et al.RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 24, 2015
Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR DatabaseEmilia Gvozdenović, Ron Wolterbeek, Cornelia F Allaart, et al.Pageof 43